A new test to predict melanoma recurrence using DNA analysis
Analytical and Clinical Validation of an EPIC 900K v2 array-based methylation assay to predict recurrence in stage II melanoma
This study is looking to create a new test that checks DNA markers in patients with stage II melanoma to better predict if their cancer might come back, helping doctors decide who might need extra treatment and who can avoid unnecessary ones.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11039026 on NIH RePORTER |
What this research studies
This research aims to develop and validate a DNA methylation assay that can predict the likelihood of recurrence in patients with stage II melanoma. By analyzing specific DNA markers, the study seeks to improve the accuracy of prognostic assessments beyond traditional histopathology. This could help identify patients who are at a higher risk of recurrence and may benefit from additional treatments, while also sparing others from unnecessary therapies. The approach involves using advanced genomic technologies to analyze tumor samples from patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with stage II melanoma who have undergone surgical resection.
Not a fit: Patients with stage I or stage III melanoma, or those who have not had surgery, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for melanoma patients, improving outcomes and reducing unnecessary treatment side effects.
How similar studies have performed: Previous research has shown promising results in using DNA methylation markers for cancer prognosis, suggesting that this approach could be effective for melanoma as well.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Polsky, David — New York University School of Medicine
- Study coordinator: Polsky, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.